Fennec Pharmaceuticals Inc. FRX.TO

FRX.TO Company Overview

Fennec Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on the development and commercialization of therapies designed to reduce treatment-related toxicities in oncology. The company operates within the pharmaceutical and oncology supportive care industries, with its primary commercial focus centered on preserving hearing in pediatric cancer patients receiving cisplatin-based chemotherapy. Fennec’s principal revenue driver is PEDMARK® (sodium thiosulfate injection), an FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors. The company primarily serves pediatric oncology providers, hospitals, treatment centers, and healthcare systems in the United States.

Fennec traces its origins to earlier biotechnology operations before evolving into a focused oncology supportive-care company. The company repositioned its strategy around sodium thiosulfate-based hearing protection technologies and advanced the PEDMARK program through clinical development, regulatory approval, and commercialization. Its strategic positioning is tied to a relatively niche but clinically significant unmet medical need in pediatric oncology, supported by orphan-drug-related market protections and limited direct competition in FDA-approved cisplatin-induced ototoxicity prevention therapies.